Adidas Raises Annual Profit Bar After Yeezy Brand Aids Profit — Update
By David Sachs
Adidas raised its revenue and profit expectations after the controversial Yeezy brand contributed to a better-than-anticipated first quarter.
The German shoe and sports apparel company said Tuesday that it now expects operating profit to finish the year at around 700 million euros ($743.7 million) compared with its previous forecast of EUR500 million.
After terminating its contract with Yeezy namesake Kanye West last year, the company decided to sell the inventory rather than write it off. Adidas's release of Yeezy apparel generated revenue of about EUR150 million and an operating profit of around EUR50 million in the first quarter, the company said. Its remaining inventory will be sold at cost, contributing to revenue but not profit, the company said.
Adidas's upgrade came after first-quarter revenue rose 4% on year to EUR5.46 billion, above a Visible Alpha consensus of 3.1%. Its gross margin improved to 51% from 45% a year prior, while operating profit jumped to EUR336 million from EUR60 million.
Revenue adjusted for currency effects is now expected to grow at a rate in the mid-to-high single digits compared with previous expectations of mid-single-digit growth, the sportswear giant said.
Despite the results, Adidas still expects currency-exchange effects to constrain profitability, revenue and gross margin this year, it said.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
April 16, 2024 12:36 ET (16:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks